{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/dyspepsia-proven-functional/prescribing-information/bismuth/","result":{"pageContext":{"chapter":{"id":"348b1111-2664-52e1-9fd6-2d26abd69bcb","slug":"bismuth","fullItemName":"Bismuth","depth":2,"htmlHeader":"<!-- begin field 4b1a49e9-0f53-47c4-a8cb-a74701657bdb --><h2>Bismuth</h2><!-- end field 4b1a49e9-0f53-47c4-a8cb-a74701657bdb -->","summary":"","htmlStringContent":"<!-- begin item c77405bc-fd93-4c0b-aaf4-a74701657d7d --><!-- end item c77405bc-fd93-4c0b-aaf4-a74701657d7d -->","topic":{"id":"5cc1cb73-764f-51c5-bc62-44f807111272","topicId":"36754870-050c-4543-8dfe-bee25a1d10bb","topicName":"Dyspepsia - proven functional","slug":"dyspepsia-proven-functional","lastRevised":"Last revised in October 2018","chapters":[{"id":"8b6fdb09-e6f3-5061-8539-ae2f57647698","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"63a6aa45-5022-5194-bebc-bd4481b831fe","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"6cdc4376-525a-5e58-8be2-dd0831642d02","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"257ffcf8-d6ac-58d1-b852-f9bb7329f249","slug":"changes","fullItemName":"Changes"},{"id":"d05055eb-ebd0-5056-b860-1ea85daeb311","slug":"update","fullItemName":"Update"}]},{"id":"b6f4608e-164d-578d-8142-8b175799683f","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"bf8575af-2f9b-5729-a628-5efb1ed0411d","slug":"goals","fullItemName":"Goals"},{"id":"761ef9c0-39a0-5dd7-9216-2dc7963b0a6a","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"694c1d21-0d63-5dc6-bb90-b5acdbeb64ab","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"9244dd4a-0551-5975-b909-6d728dfadcdd","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"9029a91f-3843-5e59-8544-cb7adfa2c457","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"19b1713f-a518-57e7-a0c1-cdb48d0b4a0d","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"e265526e-adb9-5805-aedd-2e2bc77bb54c","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"93b80ba3-9d73-5fc5-8b0e-7a57de8d6107","slug":"definition","fullItemName":"Definition"},{"id":"8f596c75-9a83-5d33-8b9a-4d18a9e24e2e","slug":"prevalence","fullItemName":"Prevalence"},{"id":"0a9f461a-38b9-56d1-8511-e41e822e0e8a","slug":"complications","fullItemName":"Complications"},{"id":"e7524b44-b1cf-50d9-806d-bd52695ec307","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"a156deba-ce54-58e0-8984-13e20203cd70","fullItemName":"Management","slug":"management","subChapters":[{"id":"ff03390b-be65-558d-83cf-6808e0b84339","slug":"management-of-functional-dyspepsia","fullItemName":"Scenario: Management of functional dyspepsia"}]},{"id":"40a9d515-33a2-5915-b7db-28a3edf79724","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"c3d76d92-046e-5ac3-84fa-c59eff3cd774","slug":"proton-pump-inhibitors","fullItemName":"Proton pump inhibitors"},{"id":"8ad244d5-29e6-5577-8efb-eae73fd2faad","slug":"h2-receptor-antagonists","fullItemName":"H2-receptor antagonists"},{"id":"29d86046-683d-5047-a344-9b0961e8916a","slug":"amoxicillin","fullItemName":"Amoxicillin"},{"id":"891aafa8-13c0-5175-b0ac-580bd4cbe1b8","slug":"clarithromycin","fullItemName":"Clarithromycin"},{"id":"c11610d4-e4be-5dbb-baf5-5414f7bea599","slug":"metronidazole","fullItemName":"Metronidazole"},{"id":"a8c93904-08fc-57a4-b238-068ab96b5615","slug":"tetracycline","fullItemName":"Tetracycline"},{"id":"6075addb-8b4a-5e26-9d73-a9cd48dd70f3","slug":"levofloxacin","fullItemName":"Levofloxacin"},{"id":"348b1111-2664-52e1-9fd6-2d26abd69bcb","slug":"bismuth","fullItemName":"Bismuth"}]},{"id":"2d629b23-aa42-5503-980b-2c202de4c387","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"4be75458-608e-5c04-9441-7001ced7fc6d","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"6ad0185f-1607-5a33-9e94-892b09578c17","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"6489fce3-cac9-583f-a217-70ba5562de71","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"e29927f4-a004-5126-a503-f1045ce72a28","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"ca579371-2f3e-59ad-887e-7215f885a62a","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"de65b79c-b356-54be-a611-9a871e60c85e","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"43271e4f-f094-520d-bd20-f6582fc6ba97","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"40a9d515-33a2-5915-b7db-28a3edf79724","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"e0580bf1-7e1f-5c7d-a2a9-f38f3d344498","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 5bb68a82-ce1e-4377-ac3e-a74b008fd62e --><h3>Contraindications and cautions</h3><!-- end field 5bb68a82-ce1e-4377-ac3e-a74b008fd62e -->","summary":"","htmlStringContent":"<!-- begin item e960d410-d520-4d35-b0b5-a74b008fd1e6 --><!-- begin field 9966518d-7c6e-4128-8dd2-a74b008fd62e --><ul><li><strong>Do not prescribe bismuth (tripotassium dicitratobismuthate) to people with:</strong><ul><li>Severe renal impairment.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-proven-functional/references/\">BNF 72, 2016</a>]</p><!-- end field 9966518d-7c6e-4128-8dd2-a74b008fd62e --><!-- end item e960d410-d520-4d35-b0b5-a74b008fd1e6 -->","subChapters":[]},{"id":"86499258-cd0b-576e-b93b-c5e34a7e70cc","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 10deedc5-7b88-4bc0-a80e-a74b008fe958 --><h3>Adverse effects</h3><!-- end field 10deedc5-7b88-4bc0-a80e-a74b008fe958 -->","summary":"","htmlStringContent":"<!-- begin item 97d4d989-d90a-4f16-b978-a74b008fe902 --><!-- begin field b71af485-8b62-4011-95ff-a74b008fe958 --><ul><li>Tripotassium dicitratobismuthate (bismuth) may darken the tongue and cause black stools.</li><li>Less common adverse effects include nausea, vomiting, diarrhoea, constipation, rash, and pruritus.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-proven-functional/references/\">BNF 72, 2016</a>]</p><!-- end field b71af485-8b62-4011-95ff-a74b008fe958 --><!-- end item 97d4d989-d90a-4f16-b978-a74b008fe902 -->","subChapters":[]},{"id":"95ebbde9-82f2-5cd4-b711-b304a41cc857","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field a887cd22-32de-488a-a2fb-a74b009007fe --><h3>Drug interactions</h3><!-- end field a887cd22-32de-488a-a2fb-a74b009007fe -->","summary":"","htmlStringContent":"<!-- begin item 028c24ae-5bee-4e8d-95b3-a74b008ff9bd --><!-- begin field ad4e3d17-0688-4e96-ae70-a74b009007fe --><ul><li><strong>Possible drug interactions with tripotassium dicitratobismuthate (bismuth) include:</strong><ul><li><strong>Tetracyclines </strong>â€” bismuth reduces the absorption of tetracyclines.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/dyspepsia-proven-functional/references/\">BNF 72, 2016</a>]</p><!-- end field ad4e3d17-0688-4e96-ae70-a74b009007fe --><!-- end item 028c24ae-5bee-4e8d-95b3-a74b008ff9bd -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}